Available in Europe since 1978, trimetazidine was launched in Malaysia in 1986 as VASTAREL® 20, with the first box of this medication sold in 1987. At that time, this agent was available as three times daily dosing; this was soon followed by the modified-release formulation, ie, VASTAREL® MR®, launched in 2005 to simplify the dosing regimen. By 2007, VASTAREL® MR® had become widely available in public hospitals throughout Malaysia.The efficacy of trimetazidine in coronary artery disease (CAD) is well established – it is a well-tolerated anti-ischaemic agent with no effect on blood pressure or heart rate. It is also recommended by Malaysian and international guidelines for symptomatic relief of angina. In conjunction with the 30th anniversary of VASTAREL®, renowned local and international opinion leaders gathered at a Servier symposium, chaired by Dr Jeyamalar Rajadurai, to reflect on the evolution of CAD management and the contemporary role of trimetazidine.
Dr. Yeo Khung Keong, Dr. Wiwun Tungsubutra, Prof. Peter Collins, 20170831100001
Agents such as beta-blockers and calcium antagonists have been the cornerstone of treatment for stable angina for some time. However, new options are emerging for patients who remain inadequately controlled on conventional therapies. At a recent Menarini-sponsored symposium held during the APSC Congress 2017 in Singapore, three experts discussed the current treatment landscape, as well as changing paradigms and new effective options for patients with symptomatic angina.
Results from a survey presented at the 2017 Asia Pacific Society of Cardiology Congress indicate that 98% of respondents involved in managing patients with hypertension in Singapore recommend home blood pressure monitoring (HBPM) to patients with hypertension. However, a number of barriers remain to the effective use of out-of-office blood pressure (BP) monitoring.
Prof. Peter Collins, Prof. Giuseppe Mancia, Prof. Carolyn Lam, Dr. Choo Gim Hooi, 20170712103633
Coronary artery disease (CAD) is the leading cause of death worldwide
and is expected to remain so for the foreseeable future due to both the
ageing population and the increasing prevalence of risk factors such as
hypertension, dyslipidaemia, and diabetes. CAD is also the primary risk
factor in the development of heart failure (HF). At the 2nd Asia Pacific
CardioConnect Meeting in Hong Kong sponsored by Menarini, a group of
international and regional experts discussed current strategies for
managing stable CAD and HF and highlighted areas where patient outcomes
may be improved.
At a recent lunch symposium during the 14th Annual Scientific Meeting of the Malaysian Society of Hypertension, Dr Chow Yok Wai spoke on the importance of patient adherence in the management of hypertension, highlighting the role of combination therapy in improving treatment outcomes.
anti-inflammatory drugs (NSAIDs) are widely used to treat pain and
inflammation in patients with arthritis, but the vascular effects of some
NSAIDs have cast doubt on whether they can be used in patients at risk for
cardiovascular (CV) disease. At the American Heart Association’s Scientific
Sessions 2016 held recently in New Orleans, Louisiana, US, Professor Steven
Nissen of the Cleveland Clinic in Cleveland, Ohio, US, presented latest data
from the PRECISION (Prospective Randomized Evaluation of Celecoxib Integrated
Safety vs Ibuprofen or Naproxen) trial that evaluated the CV risk and safety
profile of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib vs
Recently, Dr Peter Lin of the Canadian Heart Research Centre spoke on treatment strategies in the management of dyslipidaemia and T2DM at an AstraZeneca-sponsored continuing medical education event. Highlights of his presentations are summarized below.
At the 17th Malaysian Society of Rheumatology/Singapore Society of Rheumatology Workshop, Associate Professor Susanna Proudman, a senior consultant in rheumatology from Australia, shared with the audience on the diagnosis and management of pulmonary arterial hypertension (PAH), with a focus on systemic sclerosis (SSc)-related PAH.
At the recent launch of an exclusive guidebook on vasodilating β-blockers for the treatment of hypertension and chronic heart failure (HF), Professor Athanasios J. Manolis delivered a lecture on why nebivolol is different from the other agents in its class.
During the 8th Diabetes Complications Conference & Grand Rounds 2016, Dr Azani Mohamed Daud talked about the guidelines on the use of ACEIs and ARBs in hypertension, and highlighted their clinical efficacies for hypertension treatment.
Red yeast rice extracts have been used in traditional medicine for centuries.1 In recent times, an extract from red yeast rice, Xuezhikang® (XZK), has been studied for its role in dyslipidaemia and cardiovascular disease. This review will look at some of the clinical trials that have done so.
Enriching salt with both potassium and magnesium in the long term may provide additional benefits for stroke patient recovery from neurologic deficits, suggests a recent study involving Taiwanese patients.